Back to top
more

Sera Prognostics (SERA)

(Delayed Data from NSDQ)

$10.04 USD

10.04
45,381

+0.08 (0.80%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $10.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sanghamitra Saha headshot

Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).

Sanghamitra Saha headshot

Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).

Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 0% and 29.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q1 Loss

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 20% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q1 Earnings Lag Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of -6.36% and 2.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

UnitedHealth (UNH) Arm to Reduce Prior Authorization Time

by Zacks Equity Research

UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.

Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?

by Zacks Equity Research

Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.

Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia

by Zacks Equity Research

The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.

All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 26.19% and 50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 8.82% and 1.92%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -55.10% and 1.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cano Health, Inc. (CANO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 25% and 2.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 50% and 4.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.